Hematologic Cancer, HSCT
Conditions
Brief summary
Application of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions. This study aims to improve transplantation outcomes with extramedullary lesions. The investigators aim to study the Post-Transplantation Evaluation of Disease-Free Survival, Overall Survival, Treatment-Related Mortality, Cumulative Recurrence Rate, Post-Transplantation Complications, and Safety Data.
Interventions
RADIATIONStereotactic body radiotherapy (SBRT)
Stereotactic Body Radiotherapy (SBRT) before bridging to HSCT
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
Subjects who meet all of the following criteria are eligible for enrollment in this study: * Age between 18 and 60 years. * A confirmed diagnosis of a hematologic malignancy, including but not limited to Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), and Multiple Myeloma (MM). * Diagnosis of extramedullary disease/lesions confirmed by one of the following: pathological biopsy, cytology, or at least one imaging modality (including PET-CT, contrast-enhanced CT, or contrast-enhanced MRI). * Presence of a suitable donor and scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). * Karnofsky Performance Status (KPS) score \> 60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2. * Has not participated in any other clinical trial involving cell-based or immunotherapies for the treatment of the primary disease. * The subject voluntarily agrees to participate in the study, demonstrates good compliance, and is willing to cooperate with follow-up procedures. * A signed informed consent form must be obtained prior to the initiation of any study-related procedures. For subjects aged 18 years or older, consent is to be provided by the subject or their immediate family member. If, in the physician's judgment, obtaining consent directly from the subject is not in the patient's best interest regarding their medical condition, the informed consent form may be signed by the legal guardian or an immediate family member of the patient
Exclusion criteria
* Previous history of one or more autologous or allogeneic stem cell transplants prior to enrollment. * Uncontrolled infection at the time of enrollment, or requirement for mechanical ventilatory assistance, or hemodynamic instability. * Severe organ dysfunction, including but not limited to hepatic or renal impairment, and heart failure. * Evidence of active HIV replication; positive HCV antibody and detectable HCV-RNA within 90 days prior to enrollment; or positive HBsAg. Known seropositivity for HIV or active hepatitis C virus. * Presence of psychiatric disorders or any other condition that, in the investigator's opinion, would compromise the subject's ability to cooperate with study treatment and monitoring requirements. * Inability or unwillingness to provide written informed consent. * Any other condition or circumstance that, in the judgment of the investigator, may pose a risk to the subject or prevent the subject from meeting or fulfilling the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | one year |
Secondary
| Measure | Time frame |
|---|---|
| relapse free survival | one year |
| cumulative incidence of relapse | one year |
| treatment related mortality | one year |
| Extramedullary disease evaluation (RECIST v1.1) | one year |
| Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | one year |
Outcome results
None listed